Evidence map›Paper›PMID 37759228›Full record

ArticleBMC biotechnology2023

Use of immunoinformatics and the simulation approach to identify Helicobacter pylori epitopes to design a multi-epitope subunit vaccine for B- and T-cells.

Zahra Ahmadzadeh Chaleshtori, Ali Asghar Rastegari, Hashem Nayeri, Abbas Doosti

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Review
  2. Article
  3. Article
  4. Biotechnologia · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Zahra Ahmadzadeh ChaleshtoriDepartment of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Ali Asghar RastegariDepartment of Molecular and Cell Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran. aliasgharrastegari72@gmail.com.
Hashem NayeriDepartment of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Abbas DoostiBiotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Islamic Azad University, Isfahan · IRIslamic Azad University of Falavarjan · IRIslamic Azad University of Shahrekord · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori cause a variety of gastric malignancies, gastric ulcers, and cause erosive diseases. The extreme nature of the bacterium and the implantation of this bacterium protects it against designing a potent drug against it. Therefore, employing a precise and effective design for a more safe and stable antigenic vaccine against this pathogen can effectively control its associated infections. This study, aimed at improving the design of multiple subunit vaccines against H. pylori, adopts multiple immunoinformatics approaches in combination with other computational approaches.

resultsIn this regard, 10 HTL, and 11 CTL epitopes were employed based on appropriate adopted MHC binding scores and c-terminal cut-off scores of 4 main selected proteins (APO, LeoA, IceA1, and IceA2). An adjuvant was added to the N end of the vaccine to achieve higher stability. For validation, immunogenicity and sensitization of physicochemical analyses were performed. The vaccine could be antigenic with significantly strong interactions with TOLK-2, 4, 5, and 9 receptors. The designed vaccine was subjected to Gromacs simulation and immune response prediction modelling that confirmed expression and immune-stimulating response efficiency. Besides, the designed vaccine showed better interactions with TLK-9.

conclusionsBased on our analyses, although the suggested vaccine could induce a clear response against H. pylori, precise laboratory validation is required to confirm its immunogenicity and safety status.

Indexed as

Helicobacter pyloriComputer SimulationEpitopesT-LymphocytesVaccines, SubunitEpitopesVaccines, SubunitHelicobacter pyloriIceA1IceA2ImmunoinformaticsLeoAVaccine

Identifiers

PMID37759228
PMCPMC10537100
OpenAlexW4387098875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.